Home » Newsletters » BioWorld Science

BioWorld Science

May 2, 2014

View Archived Issues

NKTT-320 activates immunostimulatory functions of human iNKTs

RP-5063 shows robust efficacy and safety in phase II REFRESH trial

Roche and NCI present preclinical data for RG-7787

New grant to support phase I/II trial of OXB-102 gene therapy for Parkinson's disease

RXi enrolls first patient in phase IIa keloid scar trial

Lilly nociceptin receptor antagonist proves useful for various conditions

MEI Pharma presents novel PI3Kdelta inhibitors

Vertex Pharmaceuticals synthesizes novel mannose derivatives

Advinus Therapeutics prepares novel DGAT1 inhibitors for diabetes and other disorders

InterMune selects new agents for fibrotic disorders

Allena Pharmaceuticals reports phase I data for ALLN-177

Akers Biosciences begins trials for Chlamydia assay

Vizamyl to be launched in U.S. in late 2Q 2014

Oricula Therapeutics receives NIH grant to further develop medicine to preserve hearing

Sotatercept obtains FDA orphan drug designation

Silence Therapeutics shows gene knockdown in non-human primates

Parion Sciences regains rights to ENaC inhibitors

First patient dosed in phase III study of Pulmaquin in non-cystic fibrosis bronchiectasis

Phase III program for mepolizumab in COPD begins

Favorable pharmacokinetics and pharmacodynamic activity of RPC-1063 in human volunteers

AstraZeneca offers overview of first quarter 2014

Forest Laboratories to acquire Furiex Pharmaceuticals

Ono and Nissan Chemical discontinue license agreement

FDA issues complete response letter regarding cangrelor NDA

GSK's inhaled umeclidinium approved in U.S.

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...